Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDTX NASDAQ:KNSA NASDAQ:MOR NASDAQ:OLMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTXCidara Therapeutics$104.14-1.4%$76.41$10.37▼$121.21$2.65B1.33487,052 shs121,791 shsKNSAKiniksa Pharmaceuticals International$39.25+1.0%$35.61$17.82▼$39.43$2.90B0.16631,184 shs71,918 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AOLMAOlema Pharmaceuticals$10.27-1.0%$7.68$2.86▼$13.51$703.25M2.08930,848 shs260,768 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTXCidara Therapeutics-4.54%+7.22%+57.85%+88.10%+938.54%KNSAKiniksa Pharmaceuticals International+2.56%+1.44%+6.29%+34.74%+43.61%MORMorphoSys0.00%0.00%0.00%0.00%0.00%OLMAOlema Pharmaceuticals-3.45%-3.36%+29.63%+129.93%-10.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTXCidara Therapeutics$104.14-1.4%$76.41$10.37▼$121.21$2.65B1.33487,052 shs121,791 shsKNSAKiniksa Pharmaceuticals International$39.25+1.0%$35.61$17.82▼$39.43$2.90B0.16631,184 shs71,918 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AOLMAOlema Pharmaceuticals$10.27-1.0%$7.68$2.86▼$13.51$703.25M2.08930,848 shs260,768 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTXCidara Therapeutics-4.54%+7.22%+57.85%+88.10%+938.54%KNSAKiniksa Pharmaceuticals International+2.56%+1.44%+6.29%+34.74%+43.61%MORMorphoSys0.00%0.00%0.00%0.00%0.00%OLMAOlema Pharmaceuticals-3.45%-3.36%+29.63%+129.93%-10.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDTXCidara Therapeutics 2.92Moderate Buy$151.3345.32% UpsideKNSAKiniksa Pharmaceuticals International 2.78Moderate Buy$45.4315.75% UpsideMORMorphoSys 0.00N/AN/AN/AOLMAOlema Pharmaceuticals 2.63Moderate Buy$23.33127.20% UpsideCurrent Analyst Ratings BreakdownLatest OLMA, CDTX, MOR, and KNSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/16/2025CDTXCidara TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$190.0010/13/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$38.00 ➝ $44.0010/10/2025CDTXCidara TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$200.0010/9/2025CDTXCidara TherapeuticsWBB SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetStrong-Buy$123.00 ➝ $199.0010/9/2025CDTXCidara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$110.00 ➝ $150.0010/8/2025CDTXCidara TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025KNSAKiniksa Pharmaceuticals InternationalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025OLMAOlema PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025OLMAOlema PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.0010/6/2025KNSAKiniksa Pharmaceuticals InternationalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/3/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetMarket Outperform$153.00 ➝ $173.00(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDTXCidara TherapeuticsN/AN/AN/AN/A$14.92 per shareN/AKNSAKiniksa Pharmaceuticals International$423.24M6.87N/AN/A$6.60 per share5.95MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17OLMAOlema PharmaceuticalsN/AN/AN/AN/A$7.14 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDTXCidara Therapeutics-$169.83M-$11.13N/AN/AN/AN/A-50.81%-42.46%11/6/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M$0.04979.92156.98N/A0.90%1.05%0.80%11/4/2025 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/AOLMAOlema Pharmaceuticals-$129.47M-$1.98N/AN/AN/AN/A-42.58%-38.65%11/11/2025 (Estimated)Latest OLMA, CDTX, MOR, and KNSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025OLMAOlema Pharmaceuticals-$0.44N/AN/AN/AN/AN/A11/6/2025Q3 2025CDTXCidara Therapeutics-$1.24N/AN/AN/AN/AN/A11/4/2025Q3 2025KNSAKiniksa Pharmaceuticals International$0.31N/AN/AN/AN/AN/A8/11/2025Q2 2025OLMAOlema Pharmaceuticals-$0.43-$0.51-$0.08-$0.51N/AN/A8/7/2025Q2 2025CDTXCidara Therapeutics-$1.87-$1.65+$0.22-$1.65N/AN/A7/29/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.18$0.23+$0.05$0.23$145.21 million$156.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDTXCidara TherapeuticsN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDTXCidara TherapeuticsN/A16.4516.45KNSAKiniksa Pharmaceuticals InternationalN/A3.573.16MORMorphoSys4.981.381.38OLMAOlema Pharmaceuticals0.0111.0911.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDTXCidara Therapeutics35.82%KNSAKiniksa Pharmaceuticals International53.95%MORMorphoSys18.38%OLMAOlema Pharmaceuticals91.78%Insider OwnershipCompanyInsider OwnershipCDTXCidara Therapeutics3.89%KNSAKiniksa Pharmaceuticals International53.48%MORMorphoSys0.05%OLMAOlema Pharmaceuticals16.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDTXCidara Therapeutics9025.36 million24.37 millionNo DataKNSAKiniksa Pharmaceuticals International22074.11 million34.48 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionableOLMAOlema Pharmaceuticals7068.63 million57.41 millionOptionableOLMA, CDTX, MOR, and KNSA HeadlinesRecent News About These CompaniesOlema Pharmaceuticals (NASDAQ:OLMA) Trading Up 5.7% - What's Next?October 11, 2025 | marketbeat.comWeiss Ratings Reiterates Sell (D-) Rating for Olema Pharmaceuticals (NASDAQ:OLMA)October 10, 2025 | marketbeat.comGuggenheim Initiates Coverage of Olema Pharmaceuticals (OLMA) with Buy RecommendationOctober 9, 2025 | msn.comOlema Pharmaceuticals (NASDAQ:OLMA) Earns Buy Rating from Analysts at GuggenheimOctober 8, 2025 | marketbeat.comOlema Oncology initiated with a Buy at GuggenheimOctober 8, 2025 | msn.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives $24.00 Average Target Price from BrokeragesOctober 7, 2025 | americanbankingnews.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Recommendation of "Moderate Buy" from AnalystsOctober 4, 2025 | marketbeat.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2025 | globenewswire.comOlema Pharmaceuticals (NASDAQ:OLMA) Trading Down 6.3% - Time to Sell?October 2, 2025 | marketbeat.comGoldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA)September 30, 2025 | insidermonkey.comOlema Pharmaceuticals (NASDAQ:OLMA) Trading 6.5% Higher - Here's WhySeptember 26, 2025 | marketbeat.comGoldman Sachs Group Inc. Raises Stock Position in Olema Pharmaceuticals, Inc. $OLMASeptember 20, 2025 | marketbeat.comCyrus Harmon Sells 10,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) StockSeptember 19, 2025 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon Sells 10,000 SharesSeptember 19, 2025 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 10.2% - Here's What HappenedSeptember 19, 2025 | marketbeat.comOLMA Stock Soars 47% in September So Far on Second PFE DealSeptember 12, 2025 | zacks.comPfizer collaboration with Olema may spark future bidding war - analystSeptember 3, 2025 | msn.comOlema Pharmaceuticals Grants Stock Options to New Employees Under 2022 Inducement PlanSeptember 3, 2025 | quiverquant.comQOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2025 | globenewswire.comOlema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast CancerSeptember 2, 2025 | globenewswire.comOlema Oncology to Participate in Upcoming Investor ConferencesAugust 20, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAfter the Fed's Rate Cut, PNC Could See a Mortgage Refinance BoomBy Jordan Chussler | September 21, 2025FedEx Delivers Good News: The Bottom Is in for This StockBy Thomas Hughes | September 19, 2025Why Amazon’s Latest Upgrade Might Be Its Most Important YetBy Sam Quirke | October 1, 2025Airlines Are Taking Off, With More Gains Left to Price InBy Gabriel Osorio-Mazilli | September 25, 2025Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300By Sam Quirke | September 29, 2025OLMA, CDTX, MOR, and KNSA Company DescriptionsCidara Therapeutics NASDAQ:CDTX$104.14 -1.49 (-1.41%) As of 10:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Kiniksa Pharmaceuticals International NASDAQ:KNSA$39.25 +0.39 (+0.99%) As of 10:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 10/14/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Olema Pharmaceuticals NASDAQ:OLMA$10.27 -0.10 (-0.96%) As of 10:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? Vertiv Stock Surges on Strategic CFO Hire and AI Momentum Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
